<DOC>
	<DOCNO>NCT02020369</DOCNO>
	<brief_summary>The purpose study assess safety , efficacy pharmacokinetics 2 separate dose regimen ( 75µg/kg 225 µg/kg ) Coagulation Factor VIIa ( Recombinant ) treatment bleed episode hemophilia A B patient inhibitor Factor VIII/IX</brief_summary>
	<brief_title>A Phase III Study Safety , Pharmacokinetics Efficacy Coagulation Factor VIIa ( Recombinant ) Congenital Hemophilia A B Patients With Inhibitors Factor VIII IX</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>male diagnosis congenital hemophilia A and/or B severity one following : positive inhibitor test Bethesda Unit ( BU ) ≥ 5 ( confirm screen institutional lab ) , OR BU &lt; 5 expect high anamnestic response FVIII FIX , demonstrate subject 's medical history , preclude use Factor VIII IX product treat bleeding , OR BU &lt; 5 expected refractory increase dose FVIII FIX , demonstrate subject 's medical history , preclude use Factor VIII IX product treat bleeding 12 year old , include 75 year age ( NOTE : different age restriction may apply per local regulation and/or ethical consideration ) least 3 bleed episode severity past 6 month capable understand willing comply condition protocol read , understood provide write informed consent ( patient and/or parent ( ) /legal guardian ( ) &lt; 18 year age ) coagulation disorder hemophilia A B immunosuppressed ( i.e. , patient receive systemic immunosuppressive medication , cluster differentiation 4 ( CD4 ) count screen &gt; 200/µl ) know allergy hypersensitivity rabbit platelet count &lt; 100,000/mL within one month prior first administration study drug study major surgical procedure ( e.g . orthopedic , abdominal ) receive investigational drug within 30 day first study drug administration , expect receive drug participation study clinically relevant hepatic ( AST and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal ) and/or renal impairment ( creatinine &gt; 2 time upper limit normal ) history arterial and/or venous thromboembolic event ( myocardial infarction , ischemic stroke , transient ischemic attack , deep venous thrombosis pulmonary embolism ) within 2 year prior first dose study drug , current New York Heart Association ( NYHA ) functional classification score stage II IV active malignancy ( nonmelanoma skin cancer allow ) lifethreatening disease disease condition , accord investigator 's judgment , could imply potential hazard patient , interfere trial participation trial outcome ( e.g. , history nonresponsiveness bypass product ) .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>